Crystalys Therapeutics has dosed the first patient with its once daily oral, URAT1 inhibitor dotinurad in its Phase II AMETHYST trial (NCT07535034), designed to assess dotinurad’s effectiveness in ...
Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest” or “Tempest Therapeutics”) today announced the appointment of two ...
This week, 28 th-29 th May, the Veeva R&D and Quality Summit took place in Copenhagen, Denmark. Focused on innovating together, and together advancing the industry, the Summit this year highlighted an ...
Data presentations across multiple kidney diseases illustrate the breadth of Biogen’s nephrology portfolio with EMPAVELI® (pegcetacoplan) and felzartamab, an investigational anti-CD38 monoclonal ...
Swedish Orphan Biovitrum AB engages in the research, development, manufacture, and sale of pharmaceuticals. It operates through the Haematology, Immunology, and Specialty Care segments. The ...
frontMIND randomized 899 adults (IPI 3–5; ECOG 0–2) to six 21-day cycles of tafasitamab/lenalidomide/R-CHOP vs placebo/R-CHOP, with investigator-assessed PFS as ...
Sweden’s Sobi has secured EU approval for Doptelet in primary chronic immune thrombocytopenia (ITP), an indication that the company expects to accelerate sales of the drug. Doptelet (avatrombopag) – ...
The myasthenia gravis clinical trial analysis report delivers important insights into ongoing research of 30+ pipeline ...
Total Revenues of $882.9M, up 16% Year Over YearSubscription Revenues of $730.2M, up 15% Year Over Year PLEASANTON, Calif., June 3, 2026 /PRNewswire/ -- Veeva Systems ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results